Ana Rosado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Rosado has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Angel Tejedor-Alonso
Allergy Unit Hospital Universitario Fundación Alcorcón Madrid Spain
9 shared publications - Maria Jose Torres
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
5 shared publications I. Doña
Allergy Service, Carlos Haya Hospital Malaga Spain
4 shared publications- Darío Antolín-Amérigo
Allergy Department Hospital Universitario Ramón y Cajal Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Universidad de Alcalá Madrid Spain
3 shared publications E. González‐Mancebo
Allergy Unit, University Hospital of Fuenlabrada, Madrid, Spain
3 shared publicationsG. Canto
Allergy Service, Infanta Leonor Hospital Madrid Spain
3 shared publications
Latest Publications
- 22 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3149-3151.e1
Tolerance of piperacillin-tazobactam in patients with amoxicillin allergy
- 22 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3149-3151.e1
Tolerance of piperacillin-tazobactam in patients with amoxicillin allergy
- Open Access
- 20 February 2024
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 34 (1) , 56-57
Exhaustive Diagnosis of Heat Urticaria in a Regular Clinical Practice: Report of 2 Cases
- 20 February 2024
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 34 (1) , 56-57
Open AccessExhaustive Diagnosis of Heat Urticaria in a Regular Clinical Practice: Report of 2 Cases
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (4) , 599-602
Off-label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma due to Grass Pollen: A Safe and Effective Alternative in Patients over 65 Years Old: A Series of Case Reports
Introduction: Allergic rhinoconjunctivitis and asthma are the most common IgE-mediated diseases worldwide. Allergen-specific immunotherapy (AIT) is currently the only modifying treatment for these IgE-mediated diseases, in both children and adults. Subcutaneous immunotherapy is widely used, but in patients over 65 years old there may be an increased risk of adverse reactions and a worse response to treatment. Oral immunotherapy (OIT) has been proved to be effective and safe, but currently, in most countries, it has been licensed only for patients up to 65 years old based on its technical datasheet. No studies into the efficacy and safety of this type of immunotherapy in patients older than 65 years old have been published. Case Presentation: We present four patients older than 65 years old with a diagnosis of moderate seasonal rhinoconjunctivitis and moderate-persistent seasonal pollen-induced asthma. Off-label use of oral immunotherapy (OIT) for grass pollen was prescribed, due to the severity of their rhinoconjunctivitis symptoms and worsening of asthma symptoms during the spring. Improvement in the rhinoconjunctivitis and asthma symptoms was reported by all patients since the first spring season and was maintained during the following two years of follow-up. There were no systemic reactions and only two patients initially had self-limiting oral pruritus Conclusion: Oral immunotherapy for pollens appears to be a convenient, effective, and safe option in older patients (>65 years) with comorbidities after a three-year treatment. This is, to the best of our knowledge, the first report of the off-label use of OIT in patients over 65 years old with symptoms of allergic rhinoconjunctivitis and asthma.
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (4) , 599-602
Off-label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma due to Grass Pollen: A Safe and Effective Alternative in Patients over 65 Years Old: A Series of Case Reports
Introduction: Allergic rhinoconjunctivitis and asthma are the most common IgE-mediated diseases worldwide. Allergen-specific immunotherapy (AIT) is currently the only modifying treatment for these IgE-mediated diseases, in both children and adults. Subcutaneous immunotherapy is widely used, but in patients over 65 years old there may be an increased risk of adverse reactions and a worse response to treatment. Oral immunotherapy (OIT) has been proved to be effective and safe, but currently, in most countries, it has been licensed only for patients up to 65 years old based on its technical datasheet. No studies into the efficacy and safety of this type of immunotherapy in patients older than 65 years old have been published. Case Presentation: We present four patients older than 65 years old with a diagnosis of moderate seasonal rhinoconjunctivitis and moderate-persistent seasonal pollen-induced asthma. Off-label use of oral immunotherapy (OIT) for grass pollen was prescribed, due to the severity of their rhinoconjunctivitis symptoms and worsening of asthma symptoms during the spring. Improvement in the rhinoconjunctivitis and asthma symptoms was reported by all patients since the first spring season and was maintained during the following two years of follow-up. There were no systemic reactions and only two patients initially had self-limiting oral pruritus Conclusion: Oral immunotherapy for pollens appears to be a convenient, effective, and safe option in older patients (>65 years) with comorbidities after a three-year treatment. This is, to the best of our knowledge, the first report of the off-label use of OIT in patients over 65 years old with symptoms of allergic rhinoconjunctivitis and asthma.
- 5 September 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (12) , 1314-1317
Integration of beta‐lactam allergy evaluation in a Spanish antibiotic stewardship programme
- 5 September 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (12) , 1314-1317
Integration of beta‐lactam allergy evaluation in a Spanish antibiotic stewardship programme
- 18 August 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (11) , 1079-1089
Drug Allergy Alert System in a Spanish University Hospital: Description and Dynamics of Use
Introduction: The drug allergy alert system reduces the frequency of adverse drug events, although it is subjected to collateral effects, since 80–90% of alerts are not real, and a large percentage of alerts are overridden (46.2–96.2%). We reviewed how the alert system is used at University Hospital Fundación Alcorcon (HUFA). Methods: Data were obtained from the drug allergy alert and the alert overriding notification forms (both in the period 2011–20). We also recorded drug allergy diagnoses at HUFA, drug consumption in primary care in 2016. We calculated the incidence of drug allergy alert activation, temporal trends in use, and correlations between the number of drugs in several datasets. Results: We collected 15,535 alerts. NSAIDs and penicillins were the drugs with the highest number of drug allergy alerts (36.55% and 26.91%, respectively). A correlation was found between the number of drug alerts and the type of drug allergy in HUFA in 2016. Only 6.83% of the alerts were removed, and, of these, 21.77% were reactivated. Approximately 100 overrides were recorded per year from 2016 (6.8% of 8,434 activated alerts during 2014–2020). Conclusions: The number of drug allergy alerts recorded via the drug allergy alert system of HUFA correlates with the distribution of drug allergy diagnoses in the hospital, although many of the alerts could be false positives (as per current published evidence). We detected a very low frequency of removed alerts (6.83%), a relevant frequency of reactivations (one quarter), and a very low frequency of overrides (6.8%).
- 18 August 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (11) , 1079-1089
Drug Allergy Alert System in a Spanish University Hospital: Description and Dynamics of Use
Introduction: The drug allergy alert system reduces the frequency of adverse drug events, although it is subjected to collateral effects, since 80–90% of alerts are not real, and a large percentage of alerts are overridden (46.2–96.2%). We reviewed how the alert system is used at University Hospital Fundación Alcorcon (HUFA). Methods: Data were obtained from the drug allergy alert and the alert overriding notification forms (both in the period 2011–20). We also recorded drug allergy diagnoses at HUFA, drug consumption in primary care in 2016. We calculated the incidence of drug allergy alert activation, temporal trends in use, and correlations between the number of drugs in several datasets. Results: We collected 15,535 alerts. NSAIDs and penicillins were the drugs with the highest number of drug allergy alerts (36.55% and 26.91%, respectively). A correlation was found between the number of drug alerts and the type of drug allergy in HUFA in 2016. Only 6.83% of the alerts were removed, and, of these, 21.77% were reactivated. Approximately 100 overrides were recorded per year from 2016 (6.8% of 8,434 activated alerts during 2014–2020). Conclusions: The number of drug allergy alerts recorded via the drug allergy alert system of HUFA correlates with the distribution of drug allergy diagnoses in the hospital, although many of the alerts could be false positives (as per current published evidence). We detected a very low frequency of removed alerts (6.83%), a relevant frequency of reactivations (one quarter), and a very low frequency of overrides (6.8%).
- Open Access
- 17 April 2023
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 33 (2) , 141-142
Allergy to White Kidney Beans With Cross-reactivity to Red Kidney Beans: Report of 2 Cases in Children
- 17 April 2023
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 33 (2) , 141-142
Open AccessAllergy to White Kidney Beans With Cross-reactivity to Red Kidney Beans: Report of 2 Cases in Children
- 12 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 353-365
Analysis of the Safety of Drug Allergy Workups in a Spanish University Hospital: Drug Characteristics, Type of Reaction, and Patients’ Age at the Initial Assessment
Introduction: The drug provocation test (DPT) is the gold standard for the drug allergy workup; however, it is not free from severe adverse reactions. Our aim was to obtain robust data that predict a reaction during or after the DPT at the first contact with the patient in the allergy outpatient clinic. Methods: The population of this cross-sectional study comprised all patients undergoing a drug allergy workup (clinical assessment, specific IgE, or skin tests, or DPT) at University Hospital Fundacion Alcorcon in 2016. DPTs were performed until therapeutic doses were reached, and late reactions were checked. The clinical disorders assessed in our study were classified mainly as absence of allergic reactions, morbilliform rash, urticaria, anaphylaxis, and other cutaneous disorders. Results: Physicians from the Allergy Unit programmed drug allergy workups in 977 patients (median age, 52 years; women, 64.54%). DPTs were not performed for 165 drugs involved in the reactions. Patients who did not undergo DPT were older than patients who did (positive or negative) (p = 0.0001). Positive DPT results were detected in 6.00% of DPTs performed, and most were for amoxicillin and metamizole (15–25% each). Multinomial logistic regression showed that positive reactions were more probable after DPT if the same clinical disorder was diagnosed at the first visit, including the episodes not considered allergic episodes (OR = 0.2, p < 0.001). Conclusion: We conclude that clinical practice in the diagnosis of drug allergy in our Allergy Department is safe, without over-diagnosis.
- 12 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 353-365
Analysis of the Safety of Drug Allergy Workups in a Spanish University Hospital: Drug Characteristics, Type of Reaction, and Patients’ Age at the Initial Assessment
Introduction: The drug provocation test (DPT) is the gold standard for the drug allergy workup; however, it is not free from severe adverse reactions. Our aim was to obtain robust data that predict a reaction during or after the DPT at the first contact with the patient in the allergy outpatient clinic. Methods: The population of this cross-sectional study comprised all patients undergoing a drug allergy workup (clinical assessment, specific IgE, or skin tests, or DPT) at University Hospital Fundacion Alcorcon in 2016. DPTs were performed until therapeutic doses were reached, and late reactions were checked. The clinical disorders assessed in our study were classified mainly as absence of allergic reactions, morbilliform rash, urticaria, anaphylaxis, and other cutaneous disorders. Results: Physicians from the Allergy Unit programmed drug allergy workups in 977 patients (median age, 52 years; women, 64.54%). DPTs were not performed for 165 drugs involved in the reactions. Patients who did not undergo DPT were older than patients who did (positive or negative) (p = 0.0001). Positive DPT results were detected in 6.00% of DPTs performed, and most were for amoxicillin and metamizole (15–25% each). Multinomial logistic regression showed that positive reactions were more probable after DPT if the same clinical disorder was diagnosed at the first visit, including the episodes not considered allergic episodes (OR = 0.2, p < 0.001). Conclusion: We conclude that clinical practice in the diagnosis of drug allergy in our Allergy Department is safe, without over-diagnosis.
- 30 July 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (3) , 219-233
De-labeling Beta-lactam in Adult Population
- 30 July 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (3) , 219-233
De-labeling Beta-lactam in Adult Population
- Open Access
- 18 June 2020
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 30 (3) , 211-212
Successful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report
- 18 June 2020
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 30 (3) , 211-212
Open AccessSuccessful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report